Uveitis in horses induced by interphotoreceptor retinoid-binding protein is similar to the spontaneous disease.

This research article investigates the establishment of an induced uveitis model in horses to further understand the pathology of Equine recurrent uveitis (ERU), a common inflammatory eye disease in horses.

Research Purpose and Methodology

• The primary goal of the study was to create a reliable and reproducible disease model for uveitis in horses. This model would provide insights into the pathophysiology of ERU, a frequent eye condition found in up to 10% of horses, which bears high similarity to human uveitis.
• The researchers induced the ERU-like disease in seven horses by injecting them with interphotoreceptor retinoid-binding protein (IRBP) in complete Freund’s adjuvant, a substance used to boost immune response.
• The control group of horses, which did not receive the IRBP injections, did not develop uveitis, affirming the effectiveness of the induced uveitis model.

Findings and Characteristics of the Uveitis Model

• The induced ERU resulted in a highly reproducible disease course with recurrent episodes that occur at the same intervals in all horses, and these episodes were triggered by repeated IRBP injections.
• The histological examination of the eyes showed the development of lymphoid follicle-like structures and an intraocular infiltration primarily composed of CD3(+) lymphocytes, physical patterns typical for spontaneous ERU.
• The initial T-cell response to IRBP-derived peptides was observed. The study also observed ‘epitope spreading’ – a phenomenon where the immune response extends to structurally unrelated antigens following subsequent immunizations. In this case, the immune response extended to S-antigen-derived peptides.

Implications of the Disease Model

• The created model of induced uveitis in horses presents an important tool for research. It enables comparative studies between the induced and spontaneous disease, offering a greater understanding of the condition’s pathophysiology.
• With the model, researchers can investigate potential immunomodulatory therapeutic approaches after the onset of the disease, which can potentially lead to the development of effective treatments for ERU.